Mirum Pharmaceuticals, Inc.
MIRM
Rangering i aksjer
#3278
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Aksjekurs
$82.58
Sist synkronisert: 2026-10-19
Markedsverdi
$5.36B
Endring (1 dag)
3.05%
Endring (1 år)
13.08%
Land
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
Utbytteavkastning for Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (aksjesymbol: MIRM) sin utbytteavkastning (TTM) per 2023-12-31 er: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Mirum Pharmaceuticals, Inc. (MIRM) fra 2018 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
| År | Utbytteavkastning | Endre |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
| Selskap | Utbytteavkastning | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
